SCHEMBL374346

SCHEMBL374346

COc1ccc(OC)c(N=C=O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.56
HPGD P15428 3/20 0.56
CYP3A4 P08684 3/20 0.56
TDP1 Q9NUW8 1/20 0.56
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
MAPT P10636 5/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
THRB P10828 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
GAA P10253 1/20 0.43
KDM4E B2RXH2 2/20 0.43
PKM P14618 1/20 0.43
ALOX12 P18054 1/20 0.43
MPI P34949 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29538723 1.00 ALDH1A1 (0.56) ALDH1A1HPGDCYP3A4TDP1CA12
SCHEMBL703276 0.85 ALDH1A1 (0.71) ALDH1A1HPGDCYP3A4TDP1CA12
SCHEMBL29541267 0.85 ALDH1A1 (0.71) ALDH1A1HPGDCYP3A4TDP1CA12
SCHEMBL10316751 0.85 ALDH1A1 (0.55) ALDH1A1HPGDCYP3A4TDP1CA12
SCHEMBL30940602 0.83 CA12 (0.52) ALDH1A1HPGDCYP3A4CA12CA1
SCHEMBL5891689 0.83 CYP3A4 (0.73) ALDH1A1HPGDCYP3A4TDP1CA12
SCHEMBL2487882 0.83 CYP3A4 (0.49) ALDH1A1HPGDCYP3A4TDP1CA12
SCHEMBL1457686 0.83 CA12 (0.52) ALDH1A1HPGDCYP3A4CA12CA1
SCHEMBL9359157 0.82 CYP3A4 (0.49) ALDH1A1HPGDCYP3A4TDP1CA12
SCHEMBL7529762 0.82 ALDH1A1 (0.61) ALDH1A1HPGDCYP3A4TDP1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114276303-B Ureido compounds or pharmaceutically acceptable salts thereof, and preparation method and application thereof 河南大学 2023-09-22 CN claimed
CN-115536723-A Preparation method of troostitan 天津天药药业股份有限公司 2022-12-30 CN claimed
CN-114395058-A Binuclear vanadium catalyst and preparation method and application thereof 合肥工业大学 2022-04-26 CN claimed
CN-114276303-A Ureido compound or its medicinal salt and its preparing process and application 河南大学 2022-04-05 CN claimed
CN-107176925-B Synthesis method of polysubstituted imidazoline-2, 4-diketone compound 湖北科技学院 2020-04-28 CN claimed
CN-108440977-A Modified pitch, modifying agent and preparation method for high-modulus Rut resistance concrete 长安大学 2018-08-24 CN claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
EP-4713378-A1 ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS Covestro Deutschland AG (DE) 2026-03-25 EP disclosed
WO-2025106383-A1 PYRROLIDINYL DERIVATIVES USEFUL AS HCN1/HCN 2 MODULATORS MERCK SHARP & DOHME LLC (US) 2025-05-22 WO disclosed
EP-3774961-B1 ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS COVESTRO DEUTSCHLAND AG (DE) 2025-01-15 EP disclosed
US-20240400502-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME UNIV QUEENSLAND (AU) 2024-12-05 US disclosed
WO-2024236000-A1 ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS COVESTRO DEUTSCHLAND AG (DE) 2024-11-21 WO disclosed
EP-4464727-A1 ESTERIFIED ETHANOLAMINES FOR THE PREPARATION OF ISOCYANURATE POLYMERS Covestro Deutschland AG (DE) 2024-11-20 EP disclosed
EP-0888345-A1 SIGMA-2 RECEPTORS AS BIOMARKERS OF TUMOR CELL PROLIFERATION WAKE FOREST UNIVERSITY (US) 1999-01-07 EP disclosed
EP-0880558-A1 COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED INDANE LIBRARIES ELI LILLY AND COMPANY (US) 1998-12-02 EP disclosed
WO-1998046631-A1 COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC MACROCYCLES AND PROCESSES THEREFOR ELI LILLY AND COMPANY (US) 1998-10-22 WO disclosed
EP-0816309-A1 Scavenger assisted combinatorial process for preparing libraries of urea and thiourea compounds ELI LILLY AND COMPANY (US) 1998-01-07 EP disclosed
WO-1997034892-A1 SIGMA-2 RECEPTORS AS BIOMARKERS OF TUMOR CELL PROLIFERATION WAKE FOREST UNIVERSITY (US) 1997-09-25 WO disclosed
WO-1997026300-A1 COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED INDANE LIBRARIES ELI LILLY AND COMPANY (US) 1997-07-24 WO disclosed
US-4775757-A CARDIOTONIC AND RENAL VASODILATING AGENTS ORTHO PHARMACEUTICAL CORPORATION (US) 1988-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400502-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME NLRP3, PYCARD, IAPP ALDH1A1 3558/4885HPGD 4064/4885CYP3A4 2879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.